1. In Phase 2 clinical development (for alcohol use disorder and opioid use disorder).
2. Mission: Improve Public Health by Reducing Addiction. We are developing an NCE with a novel anti-craving mechanism of action (published in Nature Med). 
3. Capital efficient: more than $15M NIH support; and as a spin-out from Gilead Sciences, building from a large prior development investment.

1. Mission: Cure obesity and Non Alcoholic Fatty Liver Disease (NAFLD) that are growing and costly pandemics in need of safe and effective therapies.
2. Strategy: Use of One Drug-Multiple Targets concept (the mode of action of our drug candidates which are microRNA analogs) to modulate several target genes involved in lipid oxidation, mitochondrial functions, thermogenesis, glucose metabolism, adipocyte differentiation, inflammation and anti-oxidation.
3. Accomplishment to date: Proofs of efficacy of oligonucleotide therapeutic agents achieved in human adipocytes in culture and in animal models.

We are developing a molecule (INV-102) that augments the DNA repair response to infection and injury.
1. INV-102 is the first molecule ever to show significant long term therapeutic benefit in animal models of ocular sulfur mustard gas injury. The military has been searching for a solution since World War I.
2. INV-102's mechanism also reduces viral replication of many common viruses, and enhances the repair of the damage they cause.
3.  In addition to being effective in the eyes, INV-102 has also shown efficacy in the lungs, thereby indicating that INV-102 has the potential to be a first line therapy for both acute ophthalmic and pulmonary infections or injuries.   

1.High unmet need responsible for 1 in 4 deaths in the US, and yet a neglected area of R and D amongst established pharma.
2. Anti-Thrombotic with unique clotting cascade FXI and XIa inhibition bringing the promise of improving treatment effectiveness with a wide therapeutic window.
3. Novel genetics-derived antibody therapy, monthly administration with potential to transform treatment SOC.

1.aTyr focuses on the extracellular functionality and signaling pathways of tRNA synthetases. Based on more than a decade of foundational science in this area, we have built a global intellectual property estate directed to all 20 human tRNA synthetases, with over 300 protein compositions patented. 2. Our lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2). ATYR1923 is a potential first-in-class, a disease-modifying therapy for patients with ILD, a group of immune-mediated disorders that cause progressive fibrosis of the lung interstitium. ATYR1923 is currently in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis.
3.aTyr Pharma's mission is to translate newly discovered biological pathways to develop innovative therapies with improved outcomes for patients with unmet medical needs.

1. VT-1161, our lead product, has demonstrated unprecedented efficacy in patients with recurrent vulvovaginal candidiasis (RVVC) and represents a major innovation in women's health as the potential first FDA-approved therapy.
2. With our global study and partners, we aim to address RVVC as a condition without geographic boundary that affects 138 million women annually and is expected to grow to 158 million by 2030.
3. Our other pipeline products include VT-1598, an agent which has demonstrated excellent activity against difficult to treat fungal infections, including Candida auris, Aspergillosis species, and pathogens responsible for Valley fever and cryptococcal meningitis.

1. Antidote has a differentiated offering to connecting patients to clinical trials -- a unique approach called precision recruitment. This includes a technology-based clinical trial search platform that allows patients to screen against all trials, a portfolio of trials, or a specific trial, a robust partner network, thorough prescreening down to labs, and site engagement. 
2. Antidote addresses industry cost of delayed trials (time and money -- up to $8M/day when a trial is delayed) as well as the human cost by connecting patients to trials. As ALS patient Eric Valor shared in a video we made of him, "Clinical trials represent life, period."
3. Antidote has made strong progress in the past year, with a new CEO at the helm. Revenue growth has been notable.

1. To revolutionize diagnostics, we are developing rapid, low-cost tests for infectious diseases to identify pathogens and treat patients in real-time at the point-of-need instead of waiting for a lab test result.
2. Our diagnostic kits will detect and identify pathogens to allow for targeted treatment and help combat antibiotic resistance.
3.Bringing diagnostics to all, our affordable and portable diagnostic kits will be able to diagnose infectious diseases anywhere in the world, even in places with low resources without clinical laboratories.  

1. Haystack:Drugs::Google:Information. Haystack’s evolvable DNA-Encoded chemical Libraries (DELs) and proprietary nDexer™ experimental algorithm combine to enable an efficient search of chemical space.
2. Facilicating Discovery through DELs & Data. Try our platform on your favorite target(s) with a simple fee-for-service agreement.
3. Not just another tool, an entire toolkit. Haystack’s platform accelerates the most expensive and data intensive portion of therapeutic development, multidimensional evaluation of compounds prior to IND filing.

1. Currently offering the only CLIA approved blood testing for stroke to improve clinical workflow and addresses 2M US annual hospital visits for stroke and focus on preventing 80% of strokes.
2. Completed 1700 patient BASE clinical trial (NCT02014896) with record enrollment and led by passionate clinicians with a vision to revolutionize stroke care.
3. Incredible leadership team and capital efficiency, completing commercial milestones on $10M capital (compared to 10x in similar companies). 2018 INVEST Diagnostic category winner, 2019 MedTech Innovator Accelerator Company.

1. We have developed biomimetic drug-like molecules that will expand access to and improve organs for transplant. This will not only result in tens of thousands more organs available for transplant and thus many lives saved, but also reduced discard, enhanced graft viability and faster recovery, shorter hospital stays, and greatly diminished healthcare costs overall.  According to the US Department of Defense, we could make significant headway to abolish some waiting lists in as little as a couple of years.
2. We used the power of biomimicry and the capabilities of nanoscience to develop molecules that mimic the function of natural antifreeze proteins.  These molecules are non-toxic, and protect functionality and viability of cells, tissues and organs. We have a significant amount of data from various studies in the last three years, including a recent breakthrough heart transplant study with a leading medical university.
3. Fewer than 37,000 transplants are completed each year, yet 1.2M people in US are in immediate need of a transplant (10x of the actual transplant list). 800,000 people die yearly whose deaths could be prevented with a transplant. And the shocker: 80% of transplantable organs are currently wasted because they cannot be preserved without functional deterioration.